AstraZeneca has paused its £200m Cambridge research site expansion, halting its entire £650m UK investment plan.
The Cambridge project had been expected to create 1,000 jobs, following the scrapped £450m vaccine facility in Merseyside.
An AstraZeneca spokesperson cited ongoing reassessment of investment needs and declined further comment.
In contrast, the company plans $50bn in US investments by 2030, including new facilities in Virginia and labs across six states.
The pause comes amid broader UK pharma setbacks, including Merck scrapping a £1bn London research centre and cutting 125 jobs.
Sir John Bell warned major pharmaceutical firms are halting UK investments due to uncertain business conditions.
Sanofi said Britain is “not a good place” for drug development and called for a clear life sciences strategy.
Eli Lilly also put its £279m London gateway lab on hold, adding to concerns over UK research investment.
Industry leaders press the government to reduce the NHS clawback rate from nearly 23% to single digits, aligning with Europe.
AstraZeneca Pauses £200m Cambridge Expansion, Halts UK Investment
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
The Mundo Post delivers powerful stories, breaking news, sports, and culture—bringing bold perspectives and timely updates to keep readers informed, inspired, and connected worldwide.
We’re social. Connect with us: